Today’s announcement of the results of CUV017 has brought with it a stream of updates from Clinuvel, on the website, YouTube and beyond.
In this post we summarise the days releases and developments.
The official announcement through the ASX – Clinuvel reports positive results in Phase III Porphyria (EPP) clinical trial
Followed by the media release – Successful drug trial results for light intolerant ‘shadow jumpers’
Clinuvel CEO Dr. Philippe Wolgen discusses the results in a webcast – Clinuvel CEO discusses positive phase III results
And for those that would rather read it, we have provided a transcript of the interview for download here.
We also today released the next in our series of discussions with EPP patients. Lyndal generously shared with us the story of her coming to terms with EPP and the impact it has had on her life to date. A life in the shadow – Erythropoietic Protoporphyria (EPP).
Watch it below, or on our website here.
